Ribo et Madrigal franchissent une première étape majeure dans le développement de nouvelles thérapies à base d'ARNsi pour la stéatohépatite associée à un dysfonctionnement métabolique (MASH)

PartnershipPositive

AI Analysis

Summary

Ribo and Madrigal Pharmaceuticals announced a major milestone in the development of new RNAi-based therapies for metabolic dysfunction-associated steatohepatitis (MASH). The companies are collaborating on this therapeutic program targeting liver disease.

Outcome Details

Ribo and Madrigal advance development of new RNAi-based therapies for MASH

Importance:6/10

Sentiment:

0.60

RNAiMASHcollaborationliver diseasemetabolic disorder

Related Companies

$06938.HK $MDGL

Read the original article

Published by PR Newswire Biotech on July 2, 2026 4:43 AM

Read Original